You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: R

    DESCRIPTION Based on the prevailing evidence we believe that a highly effective vaccine for HIV prophylaxis must induce long lasting broadly cross reactive antibody responses to envelope that exhibit antiviral activity as well as multi antigen polyfunctional CD and CD T cell responses that produce antiviral chemokines and cytokines and are possibly biased towards an effector memory phenot ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Antimicrobial Microbead Containing Topical Gel for Burn Wound Disinfection

    SBC: LYNNTECH INC.            Topic: NIAID

    DESCRIPTION provided by applicant In the U S there are more than hospitalizations annually related to burn injury with more than of these admissions to the U S burn centers resulting in more than $ billion in healthcare costs Burn wounds may become infected through patient self infection from their own normal flora or by nosocomial infection between healthcare provider or fa ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Staphylococcus aureus is a Gram positive human pathogen that causes a wide range of infections from skin and soft tissue infections SSTI to life threatening sepsis and pneumonia The pathogenicity of S aureus is dependent on numerous virulence factors including cell surface proteins and polysaccharides as well as secreted toxins An important group of thes ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Automating mosquito microdissection for a malaria PfSPZ vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION Malaria causes andgt million clinical cases and million deaths annually is responsible for andgt loss of GDP in Africa and is a serious concern for travelers and military personnel A highly effective vaccine is desperately needed and radiation attenuated Plasmodium falciparum Pf sporozoites SPZ and non attenuated PfSPZ with chloroquine chemoprophylaxis ChemoProphylax ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD

    SBC: Asclepix Therapeutics, Inc.            Topic: N

    DESCRIPTION provided by applicant Long term anti angiogenic activity of intravitreal ellipsoid particles for NVAMD Niranjan B Pandey Ph D PI Aleksander S Popel Ph D Co I Jordan J Green Ph D Co I Peter A Campochiaro M D Co I of subaward Project Summary Current therapies for wet age related macular degeneration AMD target vascular endothelial growth factors VEGFA and pla ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Portable Closed Loop Burn Resuscitation System to Optimize and Automate Fluid Resuscitation of Combat Casualties

    SBC: Arcos, Inc.            Topic: A14047

    Burns represent 5-10% of overall military casualties. Burn resuscitation requires large volume and carries the risk of severe complications or mortality resulting from under-resuscitation or over-resuscitation with severe edema and associated conditions. Traditional fluid therapy requires hourly adjustment as the burn pathophysiology changes during the resuscitation phase. Casualty evacuations (CA ...

    SBIR Phase I 2014 Department of DefenseArmy
  8. A novel broad-spectrum influenza vaccine

    SBC: KJ BIOSCIENCES LLC            Topic: NIAID

    DESCRIPTION provided by applicant Influenza viruses constantly undergo antigenic changes which pose great challenges for development of vaccines against influenza epidemics as well as pandemics There are at least known subtypes of influenza A viruses which fall into two broad phylogenetic groups Current trivalent inactivated vaccines TIV H H and B for seasonal influenza are not suit ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting endogenous sialidases for treatment of endotoxic shock

    SBC: Oncoimmune Inc            Topic: NIAID

    DESCRIPTION provided by applicant Despite the advance of antibiotics sepsis remains a major challenge to human health as both survival and incidence of severe sepsis have been largely unchanged in the last two decades It is therefore important to develop new therapeutic approaches We have recently reported that bacterial sialidases may serve as therapeutic targets for polybacterial sepsis H ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government